Media headlines about Chemed (NYSE:CHE) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Chemed earned a coverage optimism score of 0.18 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.5983879973527 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
A number of equities research analysts have recently commented on CHE shares. TheStreet raised Chemed from a “c+” rating to an “a-” rating in a research report on Friday, October 27th. Zacks Investment Research raised Chemed from a “hold” rating to a “buy” rating and set a $251.00 price objective for the company in a research report on Thursday, November 2nd. ValuEngine downgraded Chemed from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. KeyCorp reaffirmed a “hold” rating on shares of Chemed in a research report on Friday, October 27th. Finally, Royal Bank of Canada reaffirmed a “hold” rating and issued a $209.00 price objective on shares of Chemed in a research report on Tuesday, October 3rd. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $236.00.
Chemed (NYSE:CHE) traded up $3.51 during mid-day trading on Tuesday, reaching $260.05. The company’s stock had a trading volume of 140,104 shares, compared to its average volume of 102,583. Chemed has a 1 year low of $161.18 and a 1 year high of $261.91. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.48 and a current ratio of 0.50. The stock has a market capitalization of $4,100.00, a P/E ratio of 57.92, a PEG ratio of 2.87 and a beta of 1.16.
In other Chemed news, EVP Spencer S. Lee sold 1,000 shares of the business’s stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $228.45, for a total transaction of $228,450.00. Following the completion of the sale, the executive vice president now owns 36,809 shares of the company’s stock, valued at $8,409,016.05. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider David Patrick Williams sold 11,000 shares of the business’s stock in a transaction dated Wednesday, November 29th. The shares were sold at an average price of $241.28, for a total value of $2,654,080.00. Following the sale, the insider now directly owns 74,857 shares of the company’s stock, valued at approximately $18,061,496.96. The disclosure for this sale can be found here. In the last three months, insiders have sold 45,679 shares of company stock valued at $10,628,959. 4.90% of the stock is owned by company insiders.
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.